Clinical trial
Phase I/II Thymus Transplantation With Immunosuppression #950
NCT00579527 · Sumitomo Pharma Switzerland GmbH, Industry · Completed
Key facts
| NCT number | NCT00579527 |
|---|---|
| Title | Phase I/II Thymus Transplantation With Immunosuppression #950 |
| Official title | Phase I/II Trial of Thymus Transplantation With Immunosuppression, #950 |
| Acronym | #950 |
| Lead sponsor | Sumitomo Pharma Switzerland GmbH, Industry |
| Collaborators | National Institutes of Health (NIH) NIH National Institute of Allergy and Infectious Diseases (NIAID) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | DiGeorge Anomaly, Complete DiGeorge Anomaly, Complete Atypical DiGeorge Anomaly, Complete DiGeorge Syndrome, Complete Atypical DiGeorge Syndrome |
| Intervention type | Biological, Drug, Other, Procedure |
| Interventions | Cultured Thymus Tissue for Implantation (CTTI), Cultured Thymus Tissue Implantation and Parental Parathyroid Transplantation, Blood Draw, Rabbit anti-thymocyte globulin, Cyclosporine, Tacrolimus, Methylprednisolone or Prednisolone, Daclizumab, Mycophenolate mofetil |
| Enrollment | 14 |
| Start date | Dec 19, 2005 |
| Primary completion | Dec 1, 2011 |
| Completion | Dec 31, 2017 |
| First posted | Dec 24, 2007 |
| Last update posted | Mar 25, 2022 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: